aTyr Pharma (ATYR) News Today $5.14 -0.02 (-0.39%) Closing price 08/26/2025 04:00 PM EasternExtended Trading$5.15 +0.01 (+0.19%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATYR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Looking At aTyr Pharma's Recent Unusual Options ActivityAugust 25 at 4:36 PM | benzinga.comRBC Capital Sticks to Their Buy Rating for aTyr Pharma (ATYR)August 25 at 11:35 AM | theglobeandmail.comErste Asset Management GmbH Invests $1.81 Million in aTyr Pharma, Inc. $ATYRAugust 24 at 5:55 AM | marketbeat.comaTyr Pharma (NASDAQ:ATYR) Shares Gap Up After Analyst UpgradeAugust 24 at 4:37 AM | americanbankingnews.comaTyr Pharma (NASDAQ:ATYR) Given New $17.00 Price Target at Jefferies Financial GroupAugust 24 at 2:49 AM | americanbankingnews.comaTyr Pharma, Inc. (NASDAQ:ATYR) Sees Large Increase in Short InterestAugust 23, 2025 | marketbeat.comaTyr Pharma price target raised to $17 from $9 at JefferiesAugust 22, 2025 | msn.comShort Interest in aTyr Pharma, Inc. (NASDAQ:ATYR) Increases By 25.6%August 22, 2025 | americanbankingnews.comaTyr Pharma: Estimating Their Phase 3 Lung Disease Trial OutcomeAugust 20, 2025 | seekingalpha.comaTyr Pharma (NASDAQ:ATYR) Shares Down 6.3% - What's Next?August 13, 2025 | marketbeat.comKnott David M Jr Reduces Stake in aTyr Pharma, Inc. (NASDAQ:ATYR)August 12, 2025 | marketbeat.comFY2027 EPS Estimates for aTyr Pharma Reduced by AnalystAugust 12, 2025 | marketbeat.comaTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of "Buy" by BrokeragesAugust 12, 2025 | marketbeat.comaTyr Pharma (NASDAQ:ATYR) Downgraded by Wall Street Zen to "Sell"August 10, 2025 | marketbeat.comLimb Girdle Muscular Dystrophy Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Catabasis Pharma, Sarepta Therapeutics, Strykagen, Sarepta ...August 8, 2025 | theglobeandmail.comaTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate UpdateAugust 7, 2025 | globenewswire.comaTyr Pharma (ATYR) Expected to Announce Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comGSA Capital Partners LLP Buys 57,898 Shares of aTyr Pharma, Inc. (NASDAQ:ATYR)August 2, 2025 | marketbeat.comStock Traders Buy Large Volume of aTyr Pharma Put Options (NASDAQ:ATYR)July 30, 2025 | marketbeat.comDauntless Investment Group LLC Invests $515,000 in aTyr Pharma, Inc. (NASDAQ:ATYR)July 29, 2025 | marketbeat.comaTyr Pharma (NASDAQ:ATYR) Hits New 1-Year High - Here's WhyJuly 28, 2025 | marketbeat.comaTyr Pharma Shares Hit 52-Week High After Efzofitimod Trial MilestoneJuly 25, 2025 | marketwatch.comaTyr Pharma (NASDAQ:ATYR) Shares Down 8.9% - Here's What HappenedJuly 25, 2025 | marketbeat.comaTyr Pharma (NASDAQ:ATYR) Sees Large Volume Increase - Still a Buy?July 24, 2025 | marketbeat.comaTyr Pharma announces last patient visit in Phase 3 EFZO-FIT studyJuly 22, 2025 | msn.comaTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary SarcoidosisJuly 22, 2025 | globenewswire.comaTyr Pharma (NASDAQ:ATYR) Shares Gap Up - Here's WhyJuly 21, 2025 | marketbeat.comaTyr Pharma (NASDAQ:ATYR) Hits New 12-Month High - Here's What HappenedJuly 19, 2025 | marketbeat.comaTyr Pharma (NASDAQ:ATYR) Stock Price Up 7.6% - What's Next?July 18, 2025 | marketbeat.comaTyr Pharma, Inc. (NASDAQ:ATYR) Receives Consensus Recommendation of "Buy" from AnalystsJuly 18, 2025 | marketbeat.comFavourable Signals For aTyr Pharma: Numerous Insiders Acquired StockJuly 8, 2025 | finance.yahoo.comaTyr Pharma Inc Executives - MorningstarJuly 3, 2025 | morningstar.comMCannon Global Investment Management LLC Takes $143,000 Position in aTyr Pharma, Inc. (NASDAQ:ATYR)July 3, 2025 | marketbeat.comaTyr Pharma (ATYR) Gets a Buy from H.C. WainwrightJuly 2, 2025 | theglobeandmail.comaTyr Pharma to Be Added to Russell 2000® and Russell 3000® Indexes Effective June 27, 2025 - NasdaqJune 28, 2025 | nasdaq.comaTyr Pharma to be Added to the Russell 2000® and Russell 3000® IndexesJune 26, 2025 | globenewswire.comaTyr Pharma Inc Key Metrics - MorningstarJune 25, 2025 | morningstar.comMaTyr Pharma (NASDAQ:ATYR) Given New $25.00 Price Target at Wells Fargo & CompanyJune 20, 2025 | marketbeat.comWith 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backingJune 17, 2025 | finance.yahoo.com91,224 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Bank of America Corp DEJune 14, 2025 | marketbeat.comCantor Fitzgerald Predicts Atyr PHARMA FY2026 EarningsJune 11, 2025 | marketbeat.comAtyr PHARMA (NASDAQ:ATYR) Trading 6.1% Higher - Here's What HappenedJune 10, 2025 | marketbeat.comaTyr Pharma Stock Price HistoryJune 6, 2025 | investing.comaTyr Pharma reports positive interim results for SSc-ILD treatmentJune 5, 2025 | investing.comAtyr PHARMA (NASDAQ:ATYR) Sees Unusually-High Trading Volume - Here's What HappenedJune 4, 2025 | marketbeat.comAtyr PHARMA's (ATYR) Buy Rating Reiterated at HC WainwrightJune 4, 2025 | marketbeat.comaTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)June 4, 2025 | globenewswire.comMillennium Management LLC Takes $1.33 Million Position in Atyr PHARMA INC (NASDAQ:ATYR)June 4, 2025 | marketbeat.com182,625 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Northern Trust CorpJune 1, 2025 | marketbeat.comAtyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of "Buy" from BrokeragesMay 30, 2025 | marketbeat.com Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATYR Media Mentions By Week ATYR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATYR News Sentiment▼0.750.98▲Average Medical News Sentiment ATYR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATYR Articles This Week▼103▲ATYR Articles Average Week Get the Latest News and Ratings for ATYR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for aTyr Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ANI Pharmaceuticals News Vericel News Beam Therapeutics News Dyne Therapeutics News Apogee Therapeutics News Twist Bioscience News Travere Therapeutics News Biohaven News Immunocore News Cidara Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATYR) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access